October 16, 2019
Acino and Takeda Pharmaceuticals have signed an agreement for Acino to acquire parts of Takeda’s primary care portfolio in selected countries in the Middle East and Africa, and in Ukraine, for a total value in excess of US$200 million.
As part of this acquisition, Acino will acquire the rights to selected pain management, gastroenterology, cardiovascular and respiratory products from Takeda’s prescription pharmaceutical and OTC portfolio. The agreement will enable Acino to reinforce its position in the following key markets: United Arab Emirates, Egypt, Saudi Arabia, Turkey, Ukraine and South Africa, as well as several other countries.
Additionally, both parties will enter into a multi-year manufacturing and supply agreement, under which Takeda will continue to manufacture the products on behalf of Acino. The acquisition is subject to approvals by the relevant authorities and is expected to close during January – March 2020.
Latham advised Acino on the transaction with a deal team led by London corporate partners Robbie McLaren and Farah O’Brien, with associates Samantha Peacock, Stephanie Dellosa, Antonina Semyachkova, Zoe Liu, and Daria Les. Advice was also provided on technology matters by London partner Fiona Maclean and associate Mihail Krepchev, on benefits, compensation & employment by partner Stephen Brown, and on life sciences and regulatory matters by associate Frances Stocks Allen.